Investigator |
Year(s) Funded |
Institution |
Project Title |
Coral Lamartiniere, PhD |
1999-2000 |
UAB |
Genistein Programming Against Ovarian Cancer |
Theresa Strong, PhD |
1999-2000 |
UAB |
Tumor Antigens in a Syngeneic Mouse Model of Ovarian Cancer |
Donald Buchsbaum, PhD |
1999-2001 |
UAB |
Genetic Radioisotope Strategy for Treating Ovarian Cancer |
Clinton Grubbs, PhD |
1999-2001 |
UAB |
Establishment of an Ovarian Cancer Model for Evaluating Chemopreventive Agents |
Tandra Chaudhuri, PhD |
2000-2001 |
UAB |
Detection and Monitoring of Ovarian Cancer by Light-based Imaging |
Coral Lamartiniere, PhD |
2000-2001 |
UAB |
Transgene Targeting of Ovarian Cancer |
Terri Pustilnik, MD |
2000-2001 |
UAB |
Mesothelin as an Ovarian Tumor Antigen |
Winston Thompson, MD |
2000-2001 |
MSM |
Functional Analysis of Prohibitin in Ovarian Cancer |
Scott Blume, MD |
2001-2002 |
UAB |
Modulation of Ovarian Tumor Cell Proliferation and Survival |
Tandra Chaudhuri, PhD |
2001-2002 |
UAB |
Simultaneous Screening and Imaging of Ovarian Cancer |
James Lillard, PhD |
2001-2002 |
MSM |
The Role of Chemokines in Ovarian Cancer |
Fang-Tsyr Lin, M.D. |
2001-2002 |
UAB |
Regulation of LPA Signaling by GRKs and beta-Arrestins |
Jeffrey Marks, PhD |
2001-2002 |
Duke |
Three-Dimensional in situ Culturing of Normal Ovarian Surface Epithelium |
Theresa Strong, PhD |
2001-2002 |
UAB |
Evaluation of Novel Tumor Antigens as Markers for Ovarian Cancer |
Feng Wang-Johanning, Ph.D. |
2001-2002 |
UAB |
The Role of HERV in Ovarian Cancer |
Mack Barnes, MD |
2001-2003 |
UAB |
Controlled Trial of Chemoprevention Using Non-steroidal Anti-inflammatory Agents in an Avian Model of Spontaneous Ovarian Carcinogenesis |
Charles Prince, PhD |
2002-2003 |
UAB |
Osteopontin – A Biomarker for Ovarian Cancer |
Veena Rao, PhD |
2002-2003 |
MSM |
Development of Cell-based Functional Assay for BRCA1 in Ovarian Cancers |
Joellen Schildkraut, PhD |
2002-2003 |
Duke |
Genetic Determinants of Ovarian Cancer Survival |
Denise Shaw, PhD |
2002-2003 |
UAB |
Chimeric Vaccine for Ovarian Cancer |
Scott Blume, MD |
2003-2004 |
UAB |
Modulation of Ovarian Tumor Cell Proliferation and Survival by Altering IGF1R Gene Expression at the Translational Level |
David Curiel, MD, PhD |
2003-2004 |
UAB |
Dendritic Cell-based Genetic Immunotherapy for Ovarian Cancer Using a Syngeneic Mouse Model |
Julie DeLoia, PhD |
2003-2004 |
Magee-Women's 1 |
Admixture Mapping for Ovarian Cancer Susceptibility Genes |
Warner Huh, MD |
2003-2004 |
UAB |
Therapeutic Biomarker Discovery Using Novel Antibody Reagents Targeted to a Novel Molecular-based Classification of Ovarian Cancer |
Sergey Kaliberov, Ph.D. |
2003-2004 |
UAB |
Therapy of Human Ovarian Cancer Using Specific TRAIL Gene Expression in Combination with Chemotherapy |
Richard Lopez, MD |
2003-2004 |
UAB |
Exploiting Human Gamma-delta T-cells for the Immunotherapy of Ovarian Cancer |
Susan Murphy, PhD |
2003-2004 |
Duke |
Ovarian Cancer and YIN-YANG 1: Expression and Survival |
Trygve Tollefsbol, Ph.D. |
2003-2004 |
UAB |
RNA Interference of Telomerase in Ovarian Cancer Therapy |
Kurt Zinn, DVM, PhD |
2003-2004 |
UAB |
High Resolution Ultrasonography for Early Detection and Treatment Monitoring of Ovarian Cancer |
